Morepen Laboratories Secures Rs 825 Crore Multi-Year CDMO Contract from Global Pharma Firm

Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs 825 crore (USD 91 million) from a leading global pharmaceutical company. Supplies are expected to begin within 4-5 months, with execution continuing through Q1 of the 2026-27 financial year, subject to regulatory approvals. This contract is among the largest single CDMO deals in Morepen's history, reflecting its expanded manufacturing capabilities and strategic focus on long-term global supply partnerships. Chairman Sushil Suri highlighted the mandate as a milestone enhancing scale, stability, and value creation.